Business ❯ Pharmaceutical Industry

Market Trends

Drug Pricing Pricing Strategies Stock Performance Drug Development Weight Loss Drugs Novo Nordisk Drug Sales Sales Performance Generic Drugs Drug Competition

Spyre Drug Meets Midstage Target in Ulcerative Colitis, Stock Rallies

The data position Spyre to run larger placebo-controlled trials backed by a $300 million stock sale.

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

India Warns Drugmakers Over Indirect Promotion of GLP‑1 Weight‑Loss Drugs

FDA Maps New Paths for Rare-Disease Drug Evidence, Keeps Bar High

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Wegovy Pill Posts Strong U.S. Debut as U.K. Authorizes Higher 7.2 mg Injectable Dose

Next-Generation Obesity Treatments Gain Traction in 2026 as Brazil Nears Semaglutide Patent Lapse

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

Drugmakers to Lift 2026 U.S. List Prices on 350 Branded Medicines

FDA Clears Wegovy Weight-Loss Pill, U.S. Launch Set for January

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Yahoo Finance Highlights Merck and Bristol Myers as Value Plays Outside the GLP-1 Surge

Okava Launches First GLP-1 Implant Trial for Overweight Cats